 | |||
| |||
| Names | |||
|---|---|---|---|
| Preferred IUPAC name 4-Methylpentan-2-amine | |||
| Other names (4-Methylpentan-2-yl)amine | |||
| Identifiers | |||
| |||
3D model (JSmol) | |||
| ChemSpider | |||
| ECHA InfoCard | 100.003.227 | ||
| UNII | |||
| |||
| |||
| Properties | |||
| C6H15N | |||
| Molar mass | 101.193 g·mol−1 | ||
| Density | 0.717 g/mL[1] | ||
| Boiling point | 108–110 °C (226–230 °F; 381–383 K)[1] | ||
| Pharmacology | |||
| Legal status | |||
| Hazards | |||
| NFPA 704 (fire diamond) | |||
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |||
1,3-Dimethylbutylamine (1,3-DMBA,dimethylbutylamine,DMBA,4-amino-2-methylpentane, orAMP), is astimulantdrugstructurally related tomethylhexanamine where abutyl group replaces thepentyl group. The compound is analiphatic amine.
The hydrochloride and citrate salts of DMBA has been identified as unapproved ingredients in someover-the-counterdietary supplements,[3][4][5] in which it is used in an apparent attempt to circumvent bans on methylhexanamine.[6] TheU.S. Food and Drug Administration (FDA) considers any dietary supplement containing DMBA to be "adulterated".[7] Despite the FDA's opposition, DMBA continues to be sold in the US.[8]
There are no known human safety studies on DMBA and its health effects are entirely unknown.[3][4][9]
DMBA is not anagonist of the rodent or humantrace amine-associated receptor 1 (TAAR1).[10]
TAAR1 activation may reduce the rewarding properties of stimulant-type drugs of abuse (AsifMalik et al., 2017; Cotter et al., 2015; Di Cara et al., 2011; Pei et al., 2015; Simmler et al., 2016) and may theoretically counteract addictive properties of other stimulants that are contained in preworkout boosters or used concomitantly. In contrast to phenethylamines, TAAR1 was not activated by the alkylamines 1,3-dimethylamylamine and 1,3-dimethylbutylamine.
-4-Methyl-2-aminopentan.svg)
-4-Methyl-2-aminopentan.svg)
